Navigation Links
Cheaper, better disease treatments expected from faster approach to developing antibodies

changes result in slightly altered antibodies that may attach more strongly to a disease protein. The interaction between the antibody and the disease protein blocks the protein from doing harm in the body, effectively short-cutting a disease process.

Georgiou, who holds the Cockrell Family Regents Chair in Engineering #9, and Chemistry and Biochemistry Professor Brent Iverson, the Warren J. and Viola Mae Raymer Professor and Distinguished Teaching Professor, previously used the antibody evolution process to engineer a similar antibody that is in late-stage, clinical trials to treat human anthrax infections. Iverson is a co-author and a collaborator on the latest research.

To test the bacterium-only system, lead author Yariv Mazor, a postdoctoral student in chemical engineering, engineered antibodies to an anthrax toxin called PA. He and Thomas Van Blarcom, a graduate student in chemical engineering, used a method called APEx, co-developed by Georgiou and Iverson's lab, to identify the bacteria-bound antibodies that attach best to the PA. Van Blarcom then took those bacteria and grew large numbers of them to begin refining the steps needed for mass-scale production of promising therapeutic antibodies.


'"/>

Source:University of Texas at Austin


Page: 1 2

Related biology news :

1. Chemists create Superbowl molecule; May lead to better health
2. Protein discovery could unlock the secret to better TB treatment
3. Signaling protein builds bigger, better bones in mice
4. Harnessing microbes, one by one, to build a better nanoworld
5. Two are better than one
6. Discovery may lead to better Candidiasis drug
7. Insects, viruses could hold key for better human teamwork in disasters
8. Atmosphere may cleanse itself better than previously thought
9. Could better mangrove habitats have spared lives in the 2004 tsunami?
10. Muscle repair: Making a good system better, faster; implications for aging, disease
11. Plant genes identified that can form basis for crops better adapted to environmental conditions
Post Your Comments:
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... A University of Minnesota research team featuring researchers from the ... Drug Design has developed a new delivery system for a ... an effective treatment for the human immunodeficiency virus (HIV). ... decitabine and gemcitabine to be delivered in pill form, marks ...
... WASHINGTONA George Washington University researcher will receive $1.3 million ... of Diabetes and Digestive and Kidney Diseases (NIDDK) for ... diabetes develops, possibly informing the development of novel treatments ... important given 150 million people worldwide suffer from type ...
... regularly, but still aren,t seeing improvements in your health, there ... report published in the September issue of The ... may not be the problem, but what,s in what you ... evidences for rethinking the way of addressing risk assessment especially ...
Cached Biology News:Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs 2Type 2 diabetes study to examine role amylin plays in disease 2'Safe' levels of environmental pollution may have long-term health consequences 2
(Date:5/28/2015)... 2015 Celsion Corporation (the "Company") (NASDAQ: ... from two institutional healthcare investors to purchase an aggregate ... in an at-the-market registered direct offering and a concurrent ... The Company entered into a definitive purchase agreement ... to sell an aggregate of 3,000,000 shares of its ...
(Date:5/28/2015)... 28, 2015 BioNorth Texas (BioNorthTX), ... representing the life sciences industry in northern region ... meeting at The Foundry in Dallas on April ... brought together a broad spectrum of biotech professionals ... organization's early successes in partnering with key life ...
(Date:5/28/2015)... , May 28, 2015 Biscayne ... anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology ... the 2015 ASCO Annual Meeting. The data show that ... Biscayne,s anti-cancer GHRH blockers, is present on many primary ... findings suggest that GHRH antagonists could have broad anti-cancer ...
(Date:5/28/2015)... The Fertility Centers of New England is proud ... taken on a new and expanded role as Medical ... leadership, oversight and quality assurance for the practice. , ... team of experienced reproductive endocrinologists,” said Fertility Centers of ... “Her expertise and compassionate, individualized care have helped set ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... 24, 2011 Ventana Medical Systems, Inc. (Ventana), a ... the U.S. Food and Drug Administration (FDA) for the ... with associated VIRTUOSO software and iScan Coreo Au scanner. ... workflow solution for determining HER2 (4B5) expression in breast ...
... BEIJING, Oct. 24, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, ... of the leading plasma-based biopharmaceutical companies in the People,s ... included in Forbes Magazine,s annual list of Asia,s "200 ... Company was also named to the same list for ...
... LONDON, October 24, 2011 Silence ... interference (RNAi) therapeutics company, today announced that it ... Inc. ("Mirna"), a biopharmaceutical company pioneering microRNA-based therapeutics ... Silence,s proprietary AtuPLEX™ and DBTC delivery systems for ...
Cached Biology Technology:Ventana Receives FDA Clearance for HER2 (4B5) Image Analysis and Digital Read Applications 2China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 2China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 3Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 2Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 3Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 4Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 5Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 6
... a complete assay system for the measurement ... serum or plasma. The assay incorporates the ... IDS 1,25D RIA followed by quantitation by ... to use reagents, no organic or solvent ...
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
anti-achaete...
ATP-binding cassette sub-family D member 4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-like) (PXMP1-L) (P70R). [Source:Uniprot/SWISSPROT;Acc:O14678] Antigen: Recombi...
Biology Products: